Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 5/20 | 0.50 |
| ▸ | SMARCA4 | P51532 | 4/20 | 0.50 |
| ▸ | ULK1 | O75385 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467865 | 0.94 | ULK1 (0.56) | SMARCA2SMARCA4ULK1TYK2JAK2 | |
| SCHEMBL2472073 | 0.92 | SMARCA2 (0.52) | SMARCA2SMARCA4ULK1TYK2JAK2 | |
| SCHEMBL17796425 | 0.86 | TYK2 (0.59) | SMARCA2SMARCA4TYK2JAK2JAK3 | |
| SCHEMBL22644410 | 0.82 | SMARCA2 (0.52) | SMARCA2SMARCA4ULK1TYK2JAK2 | |
| SCHEMBL1534438 | 0.79 | NPC1 (0.53) | JAK3 | |
| SCHEMBL16684845 | 0.78 | ULK1 (0.50) | ULK1JAK2JAK3CDK9DYRK1B | |
| SCHEMBL3512760 | 0.78 | TYK2 (0.81) | TYK2JAK2JAK3JAK1CDK9 | |
| SCHEMBL21670326 | 0.76 | MGLL (0.52) | ULK1ROCK2 | |
| SCHEMBL22644321 | 0.76 | MALT1 (0.58) | — | |
| SCHEMBL18094875 | 0.76 | ROCK2 (0.47) | ULK1JAK3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-12 | — | — | US | disclosed |
| WO-2020225230-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | SMARCA2 3654/4885SMARCA4 4021/4885ULK1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.